By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Juno Therapeutics 

307 Westlake Avenue North
Suite 300
Seattle  Washington    U.S.A.
Phone: 206-582-1600 Fax: n/a


SEARCH JOBS

Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies. With one of the largest ever Series A investments for a biotech startup, Juno will build on the foundation of novel immunotherapies to develop two distinct and complementary platforms – CARs and TCRs.

The CAR technology is designed to target cell surface antigens that are expressed on cancer cells. In addition, the high-affinity TCR technology can also detect alterations in intracellular proteins present in tumor cells. These treatments have the potential to reduce longer-term toxicities associated with chemotherapeutics. Our goal is to drive multiple product candidates in select hematologic and solid tumor cancers to FDA licensure. Each product candidate has the potential to treat a variety of high-risk cancers.


Key Statistics


Email: Info@junotherapeutics.com
Ownership: Private

Web Site: Juno
Employees: n/a
Symbol: JUNO
 



Industry
Biotechnology






Company News
Kite Pharma (KITE) and Juno (JUNO)'s R&D Strategy to Reshape Cancer Treatment 6/21/2016 7:25:19 AM
Juno (JUNO) and Blaze Bioscience's Success Inspires Fred Hutchinson Cancer Research Center to Spin Out More Companies Faster 6/7/2016 6:54:22 AM
ASCO2016: Juno (JUNO) Defined Composition CD19 Product Candidates Demonstrate Encouraging Clinical Outcomes And Tolerability 6/6/2016 1:49:49 PM
ASCO2016: Juno (JUNO)’s Investigational CAR T Cell Product Candidate JCAR015 Shows High Response Rates In Adults With B-Cell ALL 6/6/2016 12:16:23 PM
Juno (JUNO) To Present At June 2016 Investor Conferences 6/1/2016 4:22:21 PM
Seattle Children's And Juno (JUNO) Accelerate T-Cell Immunotherapy Clinical Trials For Children And Adults With Deadly Brain Cancers 5/26/2016 6:24:03 AM
Juno (JUNO) To Highlight Advancing Immuno-Oncology Portfolio At The 2016 ASCO Annual Meeting 5/19/2016 11:52:00 AM
Juno (JUNO) Reports First Quarter 2016 Financial Results 5/10/2016 12:06:56 PM
Juno (JUNO) To Present At The Bank of America (BAC) Merrill Lynch 2016 Health Care Conference 5/4/2016 10:18:42 AM
Juno (JUNO) To Report First Quarter 2016 Financial Results On Monday, May 9 5/3/2016 10:56:12 AM
12345678910...
//-->